Novartis has announced that its chronic obstructive pulmonary disease (COPD) therapy Seebri Breezhaler has been made available via the Scottish NHS.
The Scottish Medicines Consortium has recommended the use of the product as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD, a decision supported by positive safety and efficacy data from the phase III Glow trials.
Seebri Breezhaler is a long-acting muscarinic antagonist therapy and the second once-daily treatment in Novartis' COPD portfolio based on delivery with the Breezhaler device.
An estimated 100,000 people in Scotland live with COPD, a figure that is expected to increase by one-third in the next 20 years, making the latest product launch a potentially timely one.
Professor Andy Greening, consultant physician at Lothian University Hospitals Division, Edinburgh and professor of pulmonary disease at the University of Edinburgh, said: "It's exciting that we are now able to offer a choice of treatment options to help manage our patients COPD symptoms and improve their quality of life."
Earlier this week, the company reported positive data from a phase III trial of Bexsero, a vaccine therapy for meningococcal disease group B, showing that it was able to deliver a protective immune response with an acceptable safety profile.See all the latest jobs in Pharmaceutical